SEER Inquiry System - Search

Heme & Lymphoid Neoplasms/Histology--Myelodysplastic Neoplasm: What is the histology code for myelodysplastic neoplasm with low blasts and SF3B1 mutation with primary site bone marrow (C421) diagnosed in 2023?

Solid Tumor Rules/Histology--Lung:  What is the histology code for a lung case with a diagnosis only stated as "high-grade neuroendocrine tumor" in 2022? As the disease was advanced, limited workup was done, and no more specific diagnosis was provided. See Discussion.

Update to the Current Manual/SEER*RSA--SEER Site-specific Factor 1: The 2024 SEER Manual and SEER*RSA say that Codes 10-51 are hierarchical; use the highest code that applies (10 is highest, 51 is lowest). Should the guidance say that 51 is highest, 10 is lowest since code 10 is a HPV negative p16 test?

Summary Stage 2018--Ovary:  What is the summary stage for an ovarian primary in 2024, in which the ovary capsule was ruptured with surgical spill? See Discussion.

Solid Tumor Rules/Histology--Brain and CNS: What is the histology code for angiocentric glioma? See Discussion.

Reportability/Histology--Heme & Lymphoid Neoplasms:  How should this unusual 2023 pathology-only case be reported and coded for leukemia cutis? See Discussion.

Update to the Current Manual/Tumor Size Summary—Neoadjuvant Treatment: Would you clarify instructions in the 2024 SEER Program Coding and Staging Manual (SPCSM) for Tumor Size Summary when a patient receives neoadjuvant treatment? There seems to be a conflict with the STORE Manual. See Discussion.

EOD 2018/Primary Tumor--Breast:  We are having difficulty deciding when we can or cannot use physician-assigned TNM staging to code EOD data items if the medical record or hospital abstract documentation is unclear.  As a central registry, we are unable to query physicians for clarification. Please advise what is a “discrepancy” in the EOD General Instructions to “Use the medical record documentation to assign EOD when there is a discrepancy between the T, N, M information and the documentation in the medical record.”  See Discussion.

Reportability/Behavior--Kidney:  Is a 2022 diagnosis of “clear cell renal cell papillary tumor” on nephrectomy reportable? See Discussion.

Reportability/Histology--Heme & Lymphoid Neoplasms:  Should a non-Langerhans cell histiocytosis involving the hypothalamus and pituitary gland be accessioned as a reportable, behavior /1, CNS neoplasm? See Discussion.